AACR 2021: Human CD73 knock-in mice facilitate evaluation of in vivo efficacy of anti-human CD73 cancer immunotherapies

AACR 2021: Human CD73 knock-in mice facilitate evaluation of in vivo efficacy of anti-human CD73 cancer immunotherapies

• Hypoxia in the tumor microenvironment results in overexpression of CD73, which impairs immune function via adenosine receptors such as A2AR on immune cells. 
• Biocytogen has generated a humanized B-hCD73 mouse model and a human CD73-expressing MC38 cell line (hCD73-MC38) for both in vitro functional validation and in vivo efficacy evaluation of CD73- specific antibodies. 
• Anti-human CD73 antibodies showed robust anti-tumor efficacy in hCD73 MC38/B-hCD73 mice.
• Combined anti-human CD73 and anti-mouse PD-1 blockade exhibited greater tumor inhibition compared to monotherapies. 
• B-hCD73 mice are a powerful preclinical model for in vivo efficacy evaluation of human CD73 antibodies and combination therapies.